Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12994248 | 1.00 | CYP19A1 (0.57) | CYP19A1EPHX1ALDH1A1TSHRMAPT | |
| SCHEMBL15914460 | 1.00 | CYP19A1 (0.57) | CYP19A1EPHX1ALDH1A1TSHRMAPT | |
| SCHEMBL18832114 | 1.00 | CYP19A1 (0.57) | CYP19A1EPHX1ALDH1A1TSHRMAPT | |
| SCHEMBL10064065 | 1.00 | CYP19A1 (0.57) | CYP19A1EPHX1ALDH1A1TSHRMAPT | |
| SCHEMBL5010580 | 0.92 | CYP19A1 (0.61) | CYP19A1EPHX1ALDH1A1TSHRMAPT | |
| SCHEMBL5010581 | 0.88 | CYP19A1 (0.57) | CYP19A1EPHX1ALDH1A1TSHRMAPT | |
| SCHEMBL19900145 | 0.87 | CYP19A1 (0.56) | CYP19A1EPHX1ALDH1A1TSHRMAPT | |
| SCHEMBL13953844 | 0.87 | CYP19A1 (0.56) | CYP19A1EPHX1ALDH1A1TSHRMAPT | |
| SCHEMBL25982610 | 0.87 | CYP19A1 (0.56) | CYP19A1EPHX1ALDH1A1TSHRMAPT | |
| SCHEMBL1248258 | 0.87 | CYP19A1 (0.56) | CYP19A1EPHX1ALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 698 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3817575-B1 | SOLUBILISATION OF COOLING AGENTS OF LOW SOLUBILITY | SYMRISE AG (DE) | 2025-10-15 | — | — | EP | claimed |
| EP-3494104-B1 | WARMING SENSATION COMPOUNDS | TAKASAGO PERFUMERY CO LTD (JP) | 2023-11-15 | — | — | EP | claimed |
| EP-4103287-A1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS AND COOLING AGENTS | Symrise AG (DE) | 2022-12-21 | — | — | EP | claimed |
| WO-2022122903-A1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS AND COOLING AGENTS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| WO-2022122134-A1 | COMPOSITIONS WITH (BIO)-ALKANEDIOLS AND COOLING AGENTS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| EP-3996506-A1 | FORMULATIONS FOR CONTROL AND REPELLENCY OF BITING ARTHROPODS | Bedoukian Research, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3996505-A1 | SYNERGISTIC FORMULATIONS FOR CONTROL AND REPELLENCY OF BITING ARTHROPODS | Bedoukian Research, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| CN-109803948-B | Warming sensation compound | 高砂香料工业株式会社 | 2022-03-01 | — | — | CN | claimed |
| US-11059771-B2 | Warming sensation compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2021-07-13 | — | — | US | claimed |
| US-11034644-B2 | — | — | 2021-06-15 | — | — | US | claimed |
| US-20100273887-A1 | MIXTURES COMPRISING PELLITORIN AND USES THEREOF | SYMRISE GMBH & CO. KG (DE) | 2010-10-28 | — | — | US | claimed |
| US-20100272655-A1 | Menthylcarboxamides and Their Use as Cooling Agents | BARDSLEY KATHRYN ANNE | 2010-10-28 | — | — | US | claimed |
| CN-101784261-A | Mixtures comprising pellitorin and uses thereof | SYMRISE GMBH & CO KG | 2010-07-21 | — | — | CN | claimed |
| EP-2187871-A1 | MIXTURES COMPRISING PELLITORIN AND USES THEREOF | Symrise GmbH & Co. KG (DE) | 2010-05-26 | — | — | EP | claimed |
| CN-100577166-C | Pharmaceutical formulations with improved oral drug resistance | PROCTER & GAMBLE | 2010-01-06 | — | — | CN | claimed |
| WO-2009021558-A1 | MIXTURES COMPRISING PELLITORIN AND USES THEREOF | SYMRISE GMBH & CO. KG (DE) | 2009-02-19 | — | — | WO | claimed |
| EP-1339408-B1 | LIQUID DRUG FORMULATIONS HAVING IMPROVED ORAL TOLERABILITY | PROCTER & GAMBLE (US) | 2005-06-29 | — | — | EP | claimed |
| CN-1575175-A | Pharmaceutical formulations with improved oral drug resistance | PROCTER & GAMBLE (US) | 2005-02-02 | — | — | CN | claimed |
| EP-1339408-A1 | DRUG FORMULATION HAVING IMPROVED ORAL TOLERABILITY | THE PROCTER & GAMBLE COMPANY (US) | 2003-09-03 | — | — | EP | claimed |
| WO-2002045714-A1 | DRUG FORMULATION HAVING IMPROVED ORAL TOLERABILITY | THE PROCTER & GAMBLE COMPANY (US) | 2002-06-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059771-B2 | Warming sensation compounds | TRPA1, TRPV1, TRPV4 | CYP19A1 949/4885EPHX1 1930/4885ALDH1A1 1286/4885 |
| US-11034644-B2 | — | TRPA1, TRPV1, TRPV5 | CYP19A1 759/4885EPHX1 1372/4885ALDH1A1 593/4885 |
| US-20100272655-A1 | Menthylcarboxamides and Their Use as Cooling Agents | GMDS, CHIA, RIMKLA | CYP19A1 1635/4885EPHX1 1156/4885ALDH1A1 1671/4885 |
| US-20100273887-A1 | MIXTURES COMPRISING PELLITORIN AND USES THEREOF | NISCH, TAS2R40, TAS2R60 | CYP19A1 1917/4885EPHX1 3306/4885ALDH1A1 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.